Answers are grounded in this paper and cite their sources.
Evidence on real-world effectiveness of COVID-19 vaccination during pregnancy remains limited. Using health data from the UK, Sweden, Spain, and Norway, we emulated two target trials to estimate vaccine effectiveness (VE) of mRNA COVID-19 vaccines administered during pregnancy against COVID-19 infection, hospitalisation, and admission to an Intensive Care Unit (ICU). The first trial compares initiation of a primary (two-dose) vaccination with unvaccinated, and the second compares the receipt of a first booster (third dose) with unboosted after primary vaccination. Pregnant women receiving a first or booster vaccination were matched weekly to comparable unexposed pregnant women. A total of 62,061 and 41,096 pregnant women were included in the first and second trial, respectively. Meta-analysis across the four databases showed a VE for primary vaccination of 26·2% (95% CI 16·2–35·1) against infection and 55·6% (95% CI 44·1–64·8) against hospitalisation. For boosters, the VE was 33.6% (95% CI 1·6–56·6) against infection and 34·1% (95% CI 0·6–56·4) against hospitalisation. ICU admission outcomes were too rare to analyse. In this work, we show that primary and first-booster mRNA vaccination during pregnancy is associated to a lower risk of COVID-19-related hospitalisation, while protection against infection is more modest and heterogeneous across databases. This study of over 100,000 pregnancies in four European countries found that both initial and booster COVID-19 mRNA vaccination during pregnancy were linked to lower risks of infection and related hospital admission.
No takes yet. Share an insight, caveat, or question.
Mercadé‐Besora et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: